Previous Article | Next Article ![]()
Infection and Immunity, September 2001, p. 5606-5611, Vol. 69, No. 9
Laboratory of Mycobacterial Diseases and
Cellular Immunology, Center for Biologics Evaluation and Research,
Food and Drug Administration, Bethesda, Maryland 20892
Received 24 January 2001/Returned for modification 3 April
2001/Accepted 31 May 2001
Sequencing of the entire genome of Mycobacterium
tuberculosis identified a novel multigene family composed of two
closely related subfamilies designated PE and PE_PGRS. The major
difference between these two families is the presence of a domain
containing numerous Gly-Ala repeats extending to the C terminus of the
PE_PGRS genes. We have used a representative PE_PGRS gene from
M. tuberculosis, Rv1818c
(1818PE_PGRS), and its amino-terminal PE
region (1818PE), to investigate the immunological
response to these proteins during experimental tuberculosis and
following immunization with DNA constructs. During infection of mice
with M. tuberculosis, a significant humoral immune
response was observed against recombinant 1818PE_PGRS but not toward the
1818PE protein. Similarly, immunization with a
1818PE_PGRS DNA construct induced antibodies
directed against 1818PE_PGRS but not against
1818PE proteins, and no humoral response was
induced by 1818PE DNA. These results suggest that
certain PE_PGRS genes are expressed during infection of the host
with M. tuberculosis and that an antibody response is
directed solely against the Gly-Ala-rich PGRS domain. Conversely,
splenocytes from 1818PE-vaccinated mice but not
mice immunized with 1818PE_PGRS secreted
gamma interferon following in vitro restimulation and demonstrated
protection in the mouse tuberculosis challenge model. These results
suggest that the PE vaccine can elicit an effective cellular immune
response and that immune recognition of the PE antigen is influenced by
the Gly-Ala-rich PGRS domain.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.9.5606-5611.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Comparative Immune Response to PE and
PE_PGRS Antigens of Mycobacterium
tuberculosis
and
*
Corresponding author. Mailing address: CBER/FDA, Bldg.
29, Rm. 502, 29 Lincoln Dr. (HFM-431), Bethesda, MD 20892. Phone: (301) 496-9559. Fax: (301) 402-2776. E-mail:
Brennan{at}cber.fda.gov.
Present address: Department of Biomedical Sciences, University of
Sassari, 07100 Sassari, Italy.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|